A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Small Cell Lung Cancer
What the trial is testing?
Prexasertib
Could I receive a Placebo?
No
Enrollment Goal
133
Trial Dates
May 11, 2016 - Feb 12, 2019
How long will I be in the trial?
Your participation could last up to 1 year after the last patient enrolls in the study and if you are still receiving benefit, you may continue to receive Prexasertib through a continued access program.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.